Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption

NCT: NCT05733312 · RECRUITING

NCT IDNCT05733312
StatusRECRUITING
Start Date2024-01-24
Completion2027-01-15
SponsorMayo Clinic (OTHER)
First posted
Last updated

Brief Summary

This study seeks to determine the impact of focused ultrasound (FUS) on the composition of the tumor extracellular microenvironment. Researchers will evaluate regions that are very abnormal, as well as regions that have less evidence of disease. A sub-portion of each of these areas will be targeted by focused ultrasound. Microdialysis catheters will then be placd into each region that has and has not been exposed to FUS (total of 4 catheters) to determine how FUS impacts the the brain and tumor extracellular metabolome, including concentration of routine drugs systemically administered prior to, and during surgery. Researchers hope that this information will help reveal the relative contribution of blood-derived compounds to the tumor microenvironment. If successful, microdialysis could be leveraged in the future to simultaneously evaluate pharmacokinetic and pharmacodynamic impacts of future candidate therapies, including those delivered with the aid of FUS.

Frequently Asked Questions

What is Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption?

Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption is a clinical trial registered under NCT05733312. Current status: RECRUITING.

What is the status of NCT05733312?

The current status of NCT05733312 (Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption) is: RECRUITING.

When did Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption start?

Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption started on 2024-01-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.